The present study employs a recently reported liquid chromatography(time of flight) mass spectrometry procedure for the simultaneous analysis of 22 benzodiazepines in human urine specimens. The analysis focused on the most commonly prescribed benzodiazepines and/or their metabolites. Using this method, the limit of quantitation for the benzodiazepines tested ranged from 2 to 10 ng/mL, while the limit of detection range was 0.5 to 3.0 ng/mL. Urine specimens collected from alleged victims of drug-facilltated sexual assault (156 specimens) were tested. Only 19 out of the 22 benzodiazepines analyzed were detected in these specimens. These same specimens were previously screened for benzodiazepines by various immunoassay techniques using a 50 ng/mL cut-off level and confirmed by a gas chromatography--mass spectrometry method after acid hydrolysis to their benzophenone skeletons, thus making the identification of the specific benzodiazepine(s) involved impossible for most specimens. This study aims to offer an alternative methodology that would allow such identification for similar specimens. Additionally, the distribution of the individual benzodiazepines of interest among the 156 specimens as well as their prevalence in specimens originating in different U.S. states is presented.
Introduction
Benzodiazepines comprise a class of clinically important drugs with therapeutic activities covering a wide range of indications thus rendering them useful as tranquilizers, anticonvulsants, muscle relaxants, and sleep aids (1) . The pharmacological properties of benzodiazepines, as valuable as they are in clinical practice, are cause for serious abuse problems all over the world (2) . Such abuse has extended over the * Author to whom correspondence should be addressed.
last few years to the area of drug-facilitated sexual assault. One of the benzodiazepines that is most often implicated in drug-facilitated sexual assault cases is flunitrazepam (3, 4) , a drug that has been marketed for over 20 years for the treatment of severe sleep disorders.
In the late 1990s, F. Hoffrnan-LaRoche (Roche), the manufacturer of flunitrazepam (brand name Rohypnol), embarked on a program to determine the use of drugs, including flunitrazeparn, in alleged cases of sexual assault, by sponsoring the development of a sensitive method [gas chromatography-mass spectrometry (GC-MS)] to detect flunitrazepam rnetabolite in urine at a level below 1 ng/mL (5) and by initiating and offering a testing program of independent urine analyses to victims of alleged sexual assault in the United States. The program included testing for a wide range of drugs of abuse including alcohol. A total of 3303 urine specimens were submitted and tested under this program, and the results of the testing have been previously reported (6) . Although the testing showed only a few urine specimens to be positive for flunitrazepam (9 specimens), over 300 specimens were positive for the benzodiazepines class with a high percentage of specimens testing positive for more than one drug, indicating exposure to polypharmacy. The GC-MS method used in that study involved acid hydrolysis of the benzodiazepines to their benzophenone skeleton in order to increase the sensitivity (5), thus making impossible the determination of the benzodiazepine(s) involved in many cases.
In a previous publication (7) , the authors of the present study presented a newly developed procedure for the simultaneous analysis of 22 different benzodiazepines using liquid chromatography coupled with (time-of-flight) mass spectrometry, LC-(TOF) MS. The sensitivity of the new LC-(TOF) MS procedure was such that the limit of detection ranged from 0.5 to 3.0 ng/mL for all benzodiazepines tested. For those benzodiazepines where the SOFT DFSA Committee has recommended a maximum detection limit, the detection limit of this procedure is 5-10 times lower, except for 7-aminofluni-trazepam, where this procedure's LOD is only 2.5 times lower. The method was used to re-analyze 13 specimens that screened positive by the immunoassay used in the study mentioned but were not confirmed by the existing GC-MS method. All 13 specimens were confirmed for one or more benzodiazepines using the LC-(TOF) MS method.
The present study describes the use of the LC-(TOF) MS procedure for the analysis of 156 specimens collected nationwide from alleged victims of drug-facilitated sexual assault in an attempt to ascertain the involvement of benzodiazepines in these cases as well as the regional distribution of individual benzodiazepines within the 35 U.S. states included in this study. 1  1  1  1  OH  4  2  2  2  2  2  OK  3  1  1  1  1  1  OR  2  1  1  1  1  PA  6  4  5  5  5  1  1  SC  3  2  2  1  2  2  2  TN  7  6  6  6  6  I  I  TX  38  11  15  12  17  7  7  UT  4  2  2  1  1  1  1  1  VA  2  1  1  1  1  1  1  WA  4  2  2  2  2  1  1 Lipomed (Cambridge, MA). I~-Glusulase (glucuronidase > 90,000 units/mL and sulfatase > 10,000 units/mL) was purchased from Perkin Elmer (Shelton, CT).
Chemicals and reagents
HPLC-grade chloroform and isopropyl alcohol were obtained from VWR (West Chester, PA). Sodium carbonate, HC1, acetonitrile, and glacial acetic acid were purchased from Fisher Scientific (Fair Lawn, N J). Water for the LC mobile phase was purified in a Milli-Q system (Millipore, Bedford, MA).
Specimen preparation
Urine specimens were collected from suspected victims of drug-facilitated sexual assault by law enforcement agencies, emergency rooms, and rape crisis centers. Most of the urine specimens were collected from these individuals within 72 h of the reported incident. The specimens were collected between June 1996 and February 2000 and stored at -20~ until analyzed. All specimens used in this study were found to be positive by immunoassay and confirmed by a GC-MS procedure that involved an acid hydrolysis step; therefore, only subclasses and not individual benzodiazepines were identified.
Validation experiments
The same procedures outlined in our previous publication (7) were used for preparation of calibration curves, hydrolysis, and extraction of the victims' specimens as well as instrumentation and chromatographic conditions. Briefly, urine specimens (1-mL aliquots) were spiked with the internal standards, buffered (1 mL sodium acetate buffer, pH 5.2), and then enzyme hydrolyzed (10,000 units I~-glusulase) at 37~ for 4 h. The hydrolyzed material was then basified (1 mL 1.5 M sodium carbonate buffer) and then extracted (4 mL chloroform/isopropano], 9:1). The organic extract was then evaporated and the residue dissolved in 100 tJL MeOH for LC-MS analysis.
LC
The LC used was an Agilent (Palo Alto, CA) series 1100 coupled to an Agilent series 1100 SL MS equipped with an ESI source. All acquisitions were performed under positive ionization mode with a capillary voltage of § 4000 V over a mass range of 200-1300 ainu. Nitrogen was used as the nebulizer gas (30 psig) as well as the drying gas at a 10 L/rain at a drying gas temperature of 325~ Data acquisition and processing was done with the software Analyst TM QS (Agilent Technologies). Separation was achieved on a Luna C8 (2) column (Phenomenex, 100 x 4.6 mm i.d., 3-1Jm particle size). The mobile phase consisted of a mixture of water (0.1% acetic acid) (A) and acetonitrile (0.1% acetic acid) (B). At a flow rate of 0.3 mL/min, a gradient elution was as follows: 73% A/27% B to 40% A/60% B at 50 rain. Each run was followed by a 5-min wash with 100% acetonitrile and an equilibration period of 15 min.
Results
Benzodiazepines comprise a large class of clinically useful drugs that are prescribed for many indications depending on the most predominant pharmacological action of the individual drug (anxiolytic, sedative-hypnotic, anticonvulsant, or muscle relaxant) (8) . There are over 50 benzodiazepines mar-keted worldwide, and although a particular drug might not be approved in a given country, it is usually smuggled into that country for illicit use. time and effort to expand the panel of benzodiazepines that they may identify and quantify and resorted to other technologies such as LC-MS (10) (11) (12) (13) .
In order to improve the sensitivity of the currently accepted as the state of the art method employing GC-MS in confirming presumptive positives by immunoassay and to cover as many benzodiazepines as possible, laboratories have resorted to the (5, 6) . Although that method was valuable in confirming the majority of the imunoassay presumptive positives, the actual identity of the benzodiazepine(s) involved was often not determined. Therefore, LC-(TOF) MS was employed in the simultaneous determination of 22 different benzodiazepines and metabolites in a single run (7) . That method was used herein to analyze 156 specimens previously confirmed by a GC-MS method, with acid hydrolysis, in order to attempt to identify the actual benzodiazepine(s) involved. The specimens, originated from 35 U.S. states, were collected during the period of June 1996 to February 2000 and stored at-20~ till analysis. Table I shows the number of specimens analyzed from each state and the identity of the benzodiazepine (s) detected using the LC-(TOF) MS method. Among the states with the most specimens, Texas was the highest with 38 specimens, followed by California with 19 specimens; Indiana with 8; Florida, Michigan, and Tennessee with 7 specimens each; and Pennsylvania with 6 specimens. The other states each had 5 or fewer specimens. 
Di scussi on
It is evident from Table I that the majority of the specimens, regardless of the state, were confirmed for at least one of the following compounds: temazepam, nordiazepam, diazepam, and/or oxazepam. The next most abundant benzodiazepines were a-hydroxyalprazolam and alprazolam which were de- Max, 2.9e6 cps. 8%), 7-aminoclonazepam (15.4%), and lorazepam (11.5%) .
2-OH-Ethylflurazepam
The rest of the benzodiazepines had confirmation rates of less than 3%. Figure 3 shows the extracted ion chromatograms and mass spectrum from representative urine specimens containing the different benzodiazepines analyzed. The chromatograms show that the analytes' peaks are well resolved, with low background and good peak symmetry, with the exception of nitrazepam and 7-aminoclonazepam, which showed some tailing.
Comparison of the results of this study with the data from a previously published GC-MS method (6) shows lack of agreement between the quantitative values of the two methods; that is, with some specimens, the value obtained by the GC-bIS was higher than the value(s) obtained by the LC-bIS, while with other specimens the reverse was true. For example, the values obtained by the GC-MS method for 7-aminoclonazepam were consistently higher than those obtained by LC-bIS. This, in all probability, is because the GC-bIS results for 7-aminoclon- proving the detection limit for heavily metabolized benzodiazepines such as flunitrazepam and clonazepam.
Conclusions
In conclusion, the LC-(TOF) MS method demonstrated high sensitivity and specificity for all 22 benzodiazepines analyzed. Only 19 benzodiazepines of interest were detected in the specimens tested with the majority of the specimens confirming for oxazepam, nordiazepam, diazepam, temazepam, alprazolam and its cr metabolite, and 7-aminoclonazepam. In order to increase the confirmation rate for the benzodiazepine class, more sensitive and comprehensive methods are needed that can detect a wide range of drugs and their metabolites. Further work is needed to expand the benzodiazepines included in the standardized LC-MS panel as well as to continue to expand these studies to include all 50 U.S. states as well as to include comparison with other countries where reports of incidence of alleged drug facilitated sexual assaults have increased in occurrence.
